Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Fortis Healthcare Limited — Q3 FY25
Fortis Healthcare delivered a strong Q3 FY25 with consolidated revenue of INR 1,928 crore (+14.8% YoY) and EBITDA of INR 375 crore (+32% YoY), driven by the hospital business which grew 16.8% and expanded margins by 200 bps to 20%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare delivered a strong Q3 FY25 with consolidated revenue of INR 1,928 crore (+14.8% YoY) and EBITDA of INR 375 crore (+32% YoY), driven by the hospital business which grew 16.8% and expanded margins by 200 bps to 20%. PAT surged 82.2% to INR 231 crore, aided by a deferred tax asset. Hospital occupancy improved to 67% and ARPOB grew 9.9% to INR 2.45 crore, led by high-growth specialties like oncology (+30%) and neurosciences (+18%). The diagnostics business (Agilus) saw revenue growth of 3.5% with adjusted EBITDA margin of 21.3%, impacted by rebranding costs expected to taper by Q4. Management guided for hospital margins of 20.5% for FY25 and a medium-term target of 25%, with brownfield bed additions of 350-400 per year. Key risks include slower ramp-up of the Manesar greenfield facility and ongoing legal costs related to the open offer.
फोर्टिस हेल्थकेयर ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 1,928 करोड़ रुपये रही, जो पिछले साल से 14.8% ज्यादा है। मुनाफा 375 करोड़ रुपये रहा, जो 32% बढ़ा। अस्पताल के कारोबार ने 16.8% की बढ़त दिखाई और मुनाफे का मार्जिन 20% हो गया। कंपनी का शुद्ध मुनाफा 82.2% बढ़कर 231 करोड़ रुपये हो गया। अस्पतालों में 67% बिस्तर भरे रहे और मरीजों से प्रति बिस्तर कमाई 9.9% बढ़ी। कैंसर और न्यूरोसाइंस जैसे इलाजों की मांग बढ़ी। डायग्नोस्टिक कारोबार में 3.5% बढ़त हुई। कंपनी का लक्ष्य अगले साल 20.5% मार्जिन और 350-400 नए बिस्तर जोड़ने का है। मुख्य जोखिम नए अस्पताल की धीमी शुरुआत और कानूनी खर्च हैं।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Manesar ramp-up slower than expected
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Hospital Occupancy
67%
+3pp YoY
Occupancy improved from 64% in Q3 FY24, driven by higher patient volumes.
ARPOB (Annual Revenue Per Occupied Bed)
INR 2.45 crore
+9.9% YoY
Growth driven by case mix shift to high-ticket specialties like oncology and bone marrow transplant.
Oncology Revenue Growth
30%
+30% YoY
Oncology specialty grew 30% YoY, with hematology BMT up 44%.
Agilus Test Volumes
10.29 million
+4.5% YoY
Total tests conducted in Q3 FY25, up from 9.85 million in Q3 FY24.
What Changed vs Last Quarter
NEW
Hospital margin guidance of 20.5% for FY25
Management expects hospital EBITDA margin to reach 20.5% for the full year FY25, with a medium-term target of 25%.
NEW
Diagnostics margin guidance of 21-22% for FY25
Agilus Diagnostics is expected to deliver adjusted EBITDA margin of 21-22% for FY25.
NEW
Manesar greenfield to break even by Q1 FY26
The Manesar facility, currently at INR 5 crore monthly revenue, is expected to break even at INR 9 crore per month by Q1 FY26.
NEW
Agilus to reach industry growth of 8-10% by Q2 FY26
Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.
DROPPED
Hospital EBITDA margin expansion of 200 bps for FY25
Management reaffirmed guidance of 200 bps margin expansion for the hospital business for the full year, factoring in initial losses from Manesar.
DROPPED
Agilus EBITDA margin target of 25-26% by FY27-28
Agilus aims to achieve 25-26% EBITDA margins in 15-18 months, driven by operating leverage and cost optimization.
DROPPED
Brownfield bed additions of 350-400 beds in FY26
Management expects to add 350-400 beds in FY26 through brownfield expansions at Noida, FMRI, Anandapur, and BG Road.
DROPPED
Capex of INR 800-900 crore per year for FY25 and FY26
Annual capex includes maintenance and growth capex for both years, supporting brownfield expansions and equipment upgrades.
NEW RISK
Manesar ramp-up slower than expected
The greenfield facility posted an operating loss of INR 12-13 crore in Q3; any delay in reaching break-even could pressure margins.
NEW RISK
Agilus growth recovery may lag
Despite guidance, Agilus revenue growth has been sluggish (3.5% YoY) and rebranding costs may persist, delaying margin improvement.
NEW RISK
Legal costs and open offer uncertainty
Ongoing legal cases related to the open offer and forensic audit could result in elevated legal expenses and management distraction.
NEW RISK
Competitive intensity in hospital expansion
Aggressive bed additions by peers and potential talent wars could pressure occupancy and margins, though management downplays near-term impact.
RISK GONE
Agilus top-line growth remains sluggish
Agilus revenue grew only 3.4% YoY, trailing peers, due to brand transition impact and low-value PPP business decline. Recovery to double-digit growth is uncertain.
RISK GONE
Brownfield ramp-up may pressure near-term margins
New bed additions at Manesar and other facilities are expected to initially drag EBITDA, with Manesar break-even estimated at 15 months.
RISK GONE
Legal costs remain elevated
Legal costs related to ongoing High Court cases are higher this year due to increased hearings, with no immediate resolution expected.
RISK GONE
Seasonal occupancy dip in Q3
Festival season typically reduces occupancy in Q3, which could impact sequential revenue and margin performance.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24
Management reaffirmed guidance of 200 bps margin expansion for the hospital business for the full year, factoring in initial losses from Manesar.
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
Mentioned in Q1 FY24, Q2 FY24
Management identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
Mentioned in Q1 FY24, Q2 FY24
Rapid growth in medical oncology (lower margin) relative to surgical oncology could cap margin expansion despite absolute EBITDA growth.
Fast read
Guidance and risk preview
Management expects hospital EBITDA margin to reach 20.5% for the full year FY25, with a medium-term target of 25%.
The greenfield facility posted an operating loss of INR 12-13 crore in Q3; any delay in reaching break-even could pressure margins.
View Risks →